RDEA3170 (Verinurad), is a novel Urate Transporter 1 (URAT1) inhibitor in Phase II development. RDEA3170 combined with the xanthine oxidase (XO) inhibitor febuxostat has been shown to lower sUA in patients with recurrent gout in Phase II studies by >80%. The extensive lowering of sUA delivered by the combination presents a unique opportunity to explore whether intensive urate lowering therapy can improve kidney and/or cardiac health.